Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods

US7771742B2 · kind B2 · utility

Assignee

• Allergan, Inc. · US

Inventors

• Patrick M. Hughes · Aliso Viejo, US
• Thomas C. Malone · Irvine, US
• Gerald W. De Vries · Laguna Hills, US
• Jeffrey L. Edelman · Irvine, US
• Joan-En Chang-Lin · Tustin, US
• Jane-Guo Shiah · Irvine, US
• Thierry Nivaggioli · San Francisco, US

Key dates

• Filing date: Apr 30, 2004
• Grant date: Aug 10, 2010
• Expiry date: Feb 23, 2029

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10T428/2985
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.